LEADING THE WAY TO FAST RDS SUCCESS1,2
CUROSURF® (poractant alfa) Intratracheal Suspension is the #1 surfactant used worldwide, and the number of infants treated continues to grow.
If you haven’t used CUROSURF in your NICU, you may be surprised to learn some interesting facts about how many NICUs in the US and worldwide have chosen CUROSURF as the surfactant of choice to treat infants with RDS.
- More infants are treated with CUROSURF each year than with any other surfactant1,2
- The number of hospitals using CUROSURF has more than quadrupled across the US since 20041
- Over 20 years of clinical experience with more than 2.5 million infants treated3
Ongoing research that keeps pace with clinical practice
- Safety and efficacy established in 19 clinical trials, evaluating over 4700 patients3
- Growing clinical portfolio of clinical literature that includes over 45 published articles3
- The surfactant most widely studied for use with less invasive ventilation strategies3
- Continuing support dedicated to the advancement of neonatology research and the treatment of RDS
- Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. American Journal of Perinatology. 2004;21:109-119.
- Malloy CA, Nicoski P, Muraskas JK. Randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatrica. 2005;94:779-784.
- Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics. 1988;82:683-691.
- Wiseman LR, Bryson HM. Porcine-derived lung surfactant: a review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf®) in neonatal respiratory distress syndrome. Drugs. 1994;48:386-403.
- Verder H, Robertson B, Greisen G, et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. New England Journal of Medicine. 1994;331:1051-1055.
- Schürch S, Schürch D, Curstedt T, Robertson B. Surface activity of lipid extract surfactant in relation to film area compression and collapse. Journal of Applied Physiology. 1994;77:974-986.
- Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Archives of Disease in Childhood. 1995;72:F8-F13.
- Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation. Pediatrics. 1999;103:1-6.
- Taeusch HW, Lu K, Ramierez-Schrempp D. Improving pulmonary surfactants. Acta Pharmacologica Sinica. 2002;23(suppl):11-15.
- Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation. Pediatrics. 2004;113:e560-e563.
- Gerdes JS, Seiberlich W, Sivieri EM, et al. An open-label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources.Journal of Pediatric Pharmacology and Therapeutics. 2006;11:92-100.
- Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. Implementation of surfactant treatment during continuous positive airway pressure. Journal of Perinatology. 2007;27:422-427.